Researchers have argued that the facial prediction claims are overblown and serve Human Longevity's financial interests in proprietary genomic databases.
The integration could provide a more complete phenotypic picture that helps clinicians prioritize genetic variants that may have otherwise been missed.
"It's actually pretty difficult to build an artificially intelligent machine," according to a top Google life scientist, who is more focused on iterative machine learning.
The companies plan to use machine learning and simulation to study disease drivers and identify existing and new therapies, focusing first on cardiovascular disease.
Swiss informatics firm Sophia Genetics has moved into liquid biopsies with an update to its SOPHiA AI system, changing how clinicians treat some cancers.
Researchers are developing new algorithms and using machine-learning techniques that can integrate vast amounts of cancer omics data to identify potential therapies.
